Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT04550104 as recruiting, last updated 2025-12-19. Enrolment is 200 planned participants, an estimate. Interventions: Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390, Ceralasertib, AZD5305, Durvalumab. Primary measures include Dose limiting Toxicities. No results are posted in the registry; this does not exclude separate publications.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/